Results of Overseas Clinical Studies for KRP-104, anti-diabetes agent
August 20, 2008
Kyorin Pharmaceutical Co., Ltd (Tokyo, President: Mr. Itaru Kojo), a subsidiary of Kyorin Co., Ltd. announced that the target goals of major endpoints of overseas Ph1b (in US) and Ph2a (in US and India) clinical studies for KRP-104 were achieved. KRP-104 is a DPP-4 inhibitor originated by Kyorin Pharmaceutical and jointly filed IND to US FDA by Kyorin and ActivX Bioscience, Inc. (California, USA, Chairman, President: Dr. John W. Kozarich), a wholly owned subsidiary of Kyorin Pharmaceutical.
Please see the PDF file below for details.
